Background The prognostic value of Platelet-to-lymphocyte ratio (PLR) in patients with malignant pleural mesothelioma is still indistinct. We conducted this study to assess the prognostic significance of pretreatment PLR in patients with MPM. Aim of the Work to assess the prognostic significance of pre-treatment PLR in patients with MPM. Material and Methods we retrospectively reviewed 1!0 patients treated for MPM with chemotherapy in Ain-Shams University hospital, Clinical Oncology department between January 2013 and December 2017. Pre-treatment CBC was available for the 110 patients to calculate PLR by dividing the absolute platelet count by the absolute lymphocytic count. Results Out of 110 patients with available pre-treatment complete blood picture, population age ranged from 28 to 70 years. Male to female ratio was 5:6 .Epithelioid subtype represent 85% of cases. Stages III and IV present 48.2% and 35.5, respectively while stages I and II present 3.6% and 12.7%, respectively. The median PLR in the study population was found to be 177.9, Conclusion PLR is an easy , reproducible and inexpensive prognostic factor that needs to be more investigated in MPM.

Background Bladder cancer ranks ninth in worldwide cancer incidence and it is the second most common malignancy among Egyptian males. Urothelial carcinoma (UC) of the bladder (previously known as transitional cell carcinoma; TCC)is the predominant histologic type, the two most well-established risk factors for bladder are cigarette smoking and occupational exposure to urothelial carcinogens. Aim of the Work To analyze retrospectively the clinico-pathological features of urinary bladder cancer patients treated in Clinical Oncology Department of Ain Shams University Hospitals in Egypt. Patients and Methods All 127 eligible patients fulfilling the inclusion criteria and the medical sheets were reviewed including history, clinical examination, routine laboratory tests, radiological investigations, and follow up. Several prognostic factors were analyzed in our study including age, sex, performance status, tumor size, site, grade, extent of surgery and type of treatment as regard chemotherapy and radiotherapy. Results Among the included 127 patients, populatge ranged from 30 to 75 years. Males represented 81.9 % of the patients with a male to female ratio of 4:1. Eastern Cooperative Oncology Group (ECOG) performance status of patients at presentation was ECOG 1 in 82 patients (64.6%). The majority of the studied population presented with haematuria. The most common histological subtype in biopsied specimens was transitional cell carcinoma in 75.5% of the patients.78 patients presented with non-metastatic and 47 patients with metastatic urinary bladder cancer. The median progression-free survival (PFS) was found to be 17 months and similarly the median overall survival (OS) was 17 months. In our study we found a significant correlation between age, performance status (PS), smoking, tumor stage and the treatment modalities such as surgery and adjuvant chemotherapy with the overall survival. Conclusion The epidemiology of bladder cancer was dramatically shifted in Egypt with a lower incidence of squamous cell carcinoma (SCC), a greater incidence of TCC and older age at diagnosis. Age, PS, smoking, tumor stage and the treatment modalities such as surgery and adjuvant chemotherapy were proved to affect the overall survival.

Breast cancer is the most common malignancy in women and the second most common cause of cancerrelated death in developed countries. Despite early diagnosis of breast cancer, a large proportion (up to 40%) of breast cancer patients will develop metastatic disease that is incurable with conventional treatment. The average survival time from diagnosis of metastasis for these patients is 18-30 months, although this varies considerably according to the metastatic site 1. Conventional chemotherapy regimens based on cyclophosphamide, 5-florouracil (5-FU) and methotrexate (CMF) or an anthracycline (FAC,FEC) achieve response rates (RRs) of 40-80% in chemotherapy-naive patients, although further relapse is the rule, usually within months of stopping treatment, moreover the increasing use of chemotherapy, particularly anthracycline-based regimens, in the adjuvant sitting means that new treatment options are required for metastatic disease 2. Several

Aim of the Work: To analyze the factors that affect survival in patients with brain metastases who received whole brain radiotherapy (WBRT) and to evaluate the application of the Graded Prognostic Assessment (GPA) index for these patients. Patients and Methods: We retrospectively analyzed the data of patients who had brain metastases from solid tumors and received WBRT. The impact of different prognostic factors and GPA index on survival of these patients was estimated. Results: Between January 2005 and December 2008, 121 patients with brain metastases were treated with WBRT. The majority of patients were females (64.5%). About 60% of patients were ≥50 years and 67% of patients had a KPS ≥70. The most frequent primary tumors were breast cancer (43%) followed by lung cancer (38.8%) and most patients had extracranial metastases (76.9%).The number of brain lesions exceeded 3 in 52.1% of patients. The median overall survival (OS) was 5.00 months (95% confidence interval (CI) 4.455.55-) and the estimated 1year OS was 19.2% with (95% CI 11.826.7-). The GPA index analysis showed strong correlation with survival (p=0.001), GPA 0,1-3.00 months (95% CI 2.203.80-), GPA 1.55.00 ,2.5-months (95% CI 4.58-5.42), GPA 314 ,4-months (95% CI 11.88-16.12). In univariate analysis significant prognostic factors associated with better survival were: Female sex (p= 0.028), KPS≥70 (p= 0.001), single metastatic lesion (p= 0.034), brain metastases from breast cancer (p=0.001). Multivariate analysis confirmed theses prognostic factors to be significantly associated with better survival. Conclusion: The results of this study confirmed the validity of GPA index to justify its incorporation in future randomized studies on patients with brain metastases. Further examination of the applicability of this index in brain metastases from specific primary tumors is recommended.